Q-omics provides the consensus-scored WFDC10A profile across patient tissues and cancer cell-line models. WFDC10A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, WFDC10A is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, WFDC10A RNA expression shows 8,007 significant gene co-expression associations, with the highest sampling consensus in LGG. Together, these results highlight CHOL, COAD, and LGG as cancer lineages where WFDC10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WFDC10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WFDC10A survival associations across molecular data types. WFDC10A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WFDC10A RNA expression–survival associations across cancer types. High WFDC10A expression shows unfavorable associations in CHOL, HNSC, DLBC and THYM, but favorable associations in OV and PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for WFDC10A RNA expression.
This table summarizes WFDC10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for WFDC10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WFDC10A shows lower tumor expression in LUSC and higher tumor expression in COAD, BRCA, READ, STAD and UCEC. The COAD box plot shows higher WFDC10A RNA expression in tumor versus normal tissue (log2 FC = +0.451, t-test p < 0.001).
This table shows molecular features associated with WFDC10A in patient tissues and cancer cell lines. In patient samples, WFDC10A shows the broadest associations at the RNA and protein expression levels, with LGG recurring as the lineage with the largest associated feature set. In cancer cell lines, WFDC10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
